| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Daouda Ndiaye | Q28870686 |
| Philip J Rosenthal | Q60060211 | ||
| Liwang Cui | Q60429811 | ||
| Pradipsinh K. Rathod | Q88838215 | ||
| P2093 | author name string | Sungano Mharakurwa | |
| P2860 | cites work | Global malaria mortality between 1980 and 2010: a systematic analysis | Q20905423 |
| Spread of artemisinin resistance in Plasmodium falciparum malaria | Q21032481 | ||
| Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border | Q21032539 | ||
| Malarone treatment failure not associated with previously described mutations in the cytochrome b gene | Q21033786 | ||
| Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria | Q21245928 | ||
| Artemisinin Resistance in Plasmodium falciparum Malaria | Q22061852 | ||
| Evidence of Artemisinin-Resistant Malaria in Western Cambodia | Q22061854 | ||
| A molecular marker of artemisinin-resistant Plasmodium falciparum malaria | Q22061872 | ||
| Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study | Q24598695 | ||
| Spiroindolones, a potent compound class for the treatment of malaria | Q24606915 | ||
| Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial | Q24630683 | ||
| Association of house spraying with suppressed levels of drug resistance in Zimbabwe | Q24803104 | ||
| The interplay between drug resistance and fitness in malaria parasites | Q26998596 | ||
| Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum | Q27861931 | ||
| Disruption of a Plasmodium falciparum Multidrug Resistance-associated Protein (PfMRP) Alters Its Fitness and Transport of Antimalarial Drugs and Glutathione | Q27861935 | ||
| Artemisinin and chloroquine: do mode of action and mechanism of resistance involve the same protagonists? | Q36747313 | ||
| In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes | Q36757694 | ||
| K13-propeller polymorphisms in plasmodium falciparum parasites from sub-saharan Africa | Q36786733 | ||
| Malaria chemoprophylaxis: strategies for risk groups | Q36803894 | ||
| Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics | Q37152316 | ||
| Analysis of genetic mutations associated with anti-malarial drug resistance in Plasmodium falciparum from the Democratic Republic of East Timor. | Q37166478 | ||
| A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria | Q37190605 | ||
| Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine | Q37190763 | ||
| Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment. | Q37204143 | ||
| Chloroquine resistance before and after its withdrawal in Kenya | Q37223629 | ||
| Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies | Q37240876 | ||
| Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial | Q37272095 | ||
| In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa | Q37283105 | ||
| Malaria and quinine resistance: a medical and scientific issue between Brazil and Germany (1907-19) | Q37398997 | ||
| Selection for chloroquine-sensitive Plasmodium falciparum by wild Anopheles arabiensis in Southern Zambia | Q37425838 | ||
| Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda | Q37436582 | ||
| Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure | Q37502907 | ||
| Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. | Q37503352 | ||
| Prevalence of polymorphisms in antifolate drug resistance molecular marker genes pvdhfr and pvdhps in clinical isolates of Plasmodium vivax from Kolkata, India | Q37544364 | ||
| Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine | Q37559063 | ||
| Changes in drug sensitivity and anti-malarial drug resistance mutations over time among Plasmodium falciparum parasites in Senegal | Q37583332 | ||
| Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda | Q37731834 | ||
| Transporters as mediators of drug resistance in Plasmodium falciparum | Q37732867 | ||
| The ABCs of multidrug resistance in malaria | Q37764523 | ||
| The role of antimalarial treatment in the elimination of malaria | Q37939421 | ||
| The P-glycoprotein multidrug transporter. | Q37941756 | ||
| Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria | Q38136762 | ||
| Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial | Q38397102 | ||
| Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial | Q38399521 | ||
| Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria | Q27861937 | ||
| PfCRT and its role in antimalarial drug resistance | Q27861957 | ||
| Probing the multifactorial basis of Plasmodium falciparum quinine resistance: Evidence for a strain-specific contribution of the sodium-proton exchanger PfNHE | Q27861959 | ||
| Polymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan Children | Q27861962 | ||
| Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials | Q27976482 | ||
| Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda | Q28125904 | ||
| Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial | Q28477053 | ||
| A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial | Q28477853 | ||
| Effect of transmission reduction by insecticide-treated bednets (ITNs) on antimalarial drug resistance in western Kenya | Q28477925 | ||
| Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance | Q28478286 | ||
| In vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genes | Q28484068 | ||
| Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum | Q28649962 | ||
| Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance | Q29615118 | ||
| Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number | Q29615128 | ||
| A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole | Q30039339 | ||
| The malaria parasite's chloroquine resistance transporter is a member of the drug/metabolite transporter superfamily | Q30041677 | ||
| Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study | Q30389796 | ||
| A better resolution for integrating methods for monitoring Plasmodium falciparum resistance to antimalarial drugs | Q30486953 | ||
| Diverse chemotypes disrupt ion homeostasis in the Malaria parasite | Q30487225 | ||
| (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. | Q30610467 | ||
| Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial | Q33222370 | ||
| Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda | Q33251914 | ||
| Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review | Q33288230 | ||
| Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia | Q33344900 | ||
| No seasonal accumulation of resistant P. falciparum when high-dose chloroquine is used | Q33498521 | ||
| Seasonal distribution of anti-malarial drug resistance alleles on the island of Sumba, Indonesia | Q33507449 | ||
| A non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials--increased sensitivity of P. falciparum to chloroquine in Senegal | Q33617554 | ||
| In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda | Q33676088 | ||
| Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum | Q33680054 | ||
| Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy | Q33702580 | ||
| Association of microsatellite variations of Plasmodium falciparum Na+/H+ exchanger (Pfnhe-1) gene with reduced in vitro susceptibility to quinine: lack of confirmation in clinical isolates from Africa | Q33817484 | ||
| Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes | Q35558706 | ||
| Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children | Q35607844 | ||
| Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. | Q35647706 | ||
| Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America | Q35840784 | ||
| Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda | Q35912645 | ||
| A major genome region underlying artemisinin resistance in malaria | Q35969854 | ||
| Plasmodium falciparum transmission rate and selection for drug resistance: a vexed association or a key to successful control? | Q35975158 | ||
| The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. | Q36153724 | ||
| Mechanisms of in vitro resistance to dihydroartemisinin in Plasmodium falciparum | Q36269058 | ||
| Assessment of the molecular marker of Plasmodium falciparum chloroquine resistance (Pfcrt) in Senegal after several years of chloroquine withdrawal | Q36450797 | ||
| Clinical Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria at the China-Myanmar Border | Q36485224 | ||
| Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia | Q36512312 | ||
| Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia | Q36558472 | ||
| Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso | Q33826359 | ||
| Resistance to chloroquine unhinges vivax malaria therapeutics | Q33839067 | ||
| Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar | Q33910002 | ||
| Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children | Q33947834 | ||
| Independent origin of plasmodium falciparum antifolate super-resistance, Uganda, Tanzania, and Ethiopia | Q33950981 | ||
| Spiroindolone KAE609 for falciparum and vivax malaria | Q34085717 | ||
| In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger | Q34151002 | ||
| Transporters involved in resistance to antimalarial drugs. | Q34151405 | ||
| Differential prevalence of transporter polymorphisms in symptomatic and asymptomatic falciparum malaria infections in Uganda | Q34169765 | ||
| Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations | Q34198094 | ||
| Compensatory mutations restore fitness during the evolution of dihydrofolate reductase | Q34310777 | ||
| Different allele prevalence in the dihydrofolate reductase and dihydropteroate synthase genes in Plasmodium vivax populations from China | Q34341770 | ||
| Plasmodium prevalence and artemisinin-resistant falciparum malaria in Preah Vihear Province, Cambodia: a cross-sectional population-based study | Q34354821 | ||
| Piperaquine: a resurgent antimalarial drug. | Q34378146 | ||
| Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas | Q34407217 | ||
| Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance | Q34453540 | ||
| Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda | Q34529355 | ||
| Artemisinin-based combination treatment of falciparum malaria. | Q34731529 | ||
| Burden of complicated malaria in a densely forested Bastar region of Chhattisgarh State (Central India). | Q34757045 | ||
| Molecular epidemiology of Plasmodium vivax anti-folate resistance in India | Q34995136 | ||
| Multiple origins of Plasmodium falciparum dihydropteroate synthetase mutant alleles associated with sulfadoxine resistance in India | Q35005151 | ||
| Discovery, mechanisms of action and combination therapy of artemisinin | Q35006418 | ||
| Polymorphism of Plasmodium falciparum Na(+)/H(+) exchanger is indicative of a low in vitro quinine susceptibility in isolates from Viet Nam. | Q35069374 | ||
| High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: an urgent need to re-examine malaria drug policy | Q35074416 | ||
| Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance | Q35079297 | ||
| Malaria drug-sensitivity testing: new assays, new perspectives | Q35104740 | ||
| Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar | Q35105826 | ||
| Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates | Q35146682 | ||
| Combining indoor residual spraying and insecticide-treated nets for malaria control in Africa: a review of possible outcomes and an outline of suggestions for the future | Q35163863 | ||
| Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda | Q35188480 | ||
| Multidrug-resistant genotypes of Plasmodium falciparum, Myanmar | Q35193462 | ||
| Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker | Q35217991 | ||
| Structure and function of efflux pumps that confer resistance to drugs | Q35294152 | ||
| A thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in Gabon | Q35549781 | ||
| Fansidar-resistant falciparum malaria in Papua New Guinea. | Q54539949 | ||
| Experiment to determine if a proguanil-resistant strain of P. falciparum would respond to large doses of pyrimethamine. | Q55502424 | ||
| Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan | Q38855059 | ||
| Large differences in prevalence of Pfcrt and Pfmdr1 mutations between Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies regarding withdrawal of chloroquine? | Q38868907 | ||
| Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum | Q38980049 | ||
| The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin | Q38980054 | ||
| Fitness costs of resistance to antimalarial drugs | Q39001694 | ||
| High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana | Q39215959 | ||
| Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi | Q39254734 | ||
| Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites | Q39326401 | ||
| Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia | Q39346727 | ||
| Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness | Q39367622 | ||
| Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand | Q39370966 | ||
| Intercontinental spread of pyrimethamine-resistant malaria | Q39408056 | ||
| Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site | Q39474607 | ||
| Monitoring chloroquine resistance using Plasmodium falciparum parasites isolated from wild mosquitoes in Tanzania. | Q39516937 | ||
| Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe | Q39591275 | ||
| Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. | Q39792488 | ||
| Response of Kampuchean strains of Plasmodium falciparum to antimalarials: in-vivo assessment of quinine and quinine plus tetracycline; multiple drug resistance in vitro | Q40784576 | ||
| Drug-resistant falciparum malaria among the Mayongong Indians in the Brazilian Amazon | Q41103268 | ||
| Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar | Q41827965 | ||
| Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro | Q41846791 | ||
| pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum | Q41911870 | ||
| A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. | Q41912137 | ||
| Evidence of increased chloroquine sensitivity in Thai isolates of Plasmodium falciparum | Q41912797 | ||
| Dissecting the loci of low-level quinine resistance in malaria parasites | Q41914069 | ||
| The principal chloroquine resistance protein of Plasmodium falciparum is a member of the drug/metabolite transporter superfamily | Q41914784 | ||
| Multiple transporters associated with malaria parasite responses to chloroquine and quinine | Q41915501 | ||
| Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi | Q41915777 | ||
| Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine ('Fansidar') in a refugee camp in Thailand | Q41925042 | ||
| Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite | Q41929069 | ||
| Changes in genotypes of Plasmodium falciparum human malaria parasite following withdrawal of chloroquine in Tiwi, Kenya | Q41929428 | ||
| In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya | Q41935745 | ||
| Sensitivity of Plasmodium vivax to chloroquine in Laza City, Myanmar | Q41937411 | ||
| In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. | Q41937598 | ||
| Innate resistance to new antimalarial drugs in Plasmodium falciparum from Nigeria | Q41940520 | ||
| Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria | Q41940547 | ||
| Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro | Q41943140 | ||
| Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum | Q41943905 | ||
| Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs | Q41944385 | ||
| Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin | Q41944932 | ||
| Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum. | Q42072395 | ||
| Border malaria associated with multidrug resistance on Thailand-Myanmar and Thailand-Cambodia borders: transmission dynamic, vulnerability, and surveillance | Q42181962 | ||
| Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones | Q42620844 | ||
| Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa | Q42635798 | ||
| Intermittent preventive therapy for malaria in pregnancy: is sulfadoxine-pyrimethamine the right drug? | Q43182467 | ||
| Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets | Q43949108 | ||
| In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). | Q45270651 | ||
| Fansidar resistant falciparum malaria in Indonesia | Q47824731 | ||
| Dihydroartemisinin-piperaquine failure in Cambodia | Q47877123 | ||
| Seasonal fluctuation of drug-resistant malaria parasites: a sign of fitness cost | Q47909648 | ||
| Studies in human malaria. XXXIV. Acquired resistance to pyrimethamine (daraprim) by the Chesson strain of plasmodium vivax | Q47940624 | ||
| Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations | Q48035243 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antimalarial | Q521616 |
| malaria | Q12156 | ||
| drug resistance | Q12147416 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 57-68 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | American Journal of Tropical Medicine and Hygiene | Q15766943 |
| P1476 | title | Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network | |
| P478 | volume | 93 |
| Q55107234 | A Synergistic Transcriptional Regulation of Olfactory Genes Drives Blood-Feeding Associated Complex Behavioral Responses in the Mosquito Anopheles culicifacies. |
| Q51783218 | A comparative study of epidemiological investigations of malaria outbreaks and related deaths in two districts of Jharkhand during the same prewinter season using shoe-leather epidemiology. |
| Q94491384 | A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria |
| Q39176615 | Antimalarial Drug Resistance: A Threat to Malaria Elimination |
| Q52680643 | Antiplasmodial activity of two medicinal plants against clinical isolates of Plasmodium falciparum and Plasmodium berghei infected mice. |
| Q69347181 | Artemether for severe malaria. |
| Q58585255 | Assessment of drug resistance associated genetic diversity in Mauritanian isolates of Plasmodium vivax reveals limited polymorphism |
| Q90599698 | Bayesian evaluation of the performance of three diagnostic tests for Plasmodium falciparum infection in a low-transmission setting in Kilifi County, Kenya |
| Q41508074 | Bibliometric Analysis of Worldwide Publications on Antimalarial Drug Resistance (2006-2015). |
| Q37538688 | Caged Garcinia Xanthones, a Novel Chemical Scaffold with Potent Antimalarial Activity |
| Q93271193 | Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome |
| Q92494183 | Characterization of Biological Resistance and Successful Drug Resistance Control in Medicine |
| Q90242609 | Characterization of drug resistance and genetic diversity of Plasmodium falciparum parasites from Tripura, Northeast India |
| Q91844977 | Comparative analysis of Plasmodium falciparum dihydrofolate-reductase gene sequences from different regions of India |
| Q36906050 | Comparative assessment on the prevalence of mutations in the Plasmodium falciparum drug-resistant genes in two different ecotypes of Odisha state, India |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q40107124 | Cytokines and Chemokines in Cerebral Malaria Pathogenesis |
| Q48022994 | Diagnostic tools in childhood malaria |
| Q91007298 | Discovery and Pharmacophore Mapping of a Low-Nanomolar Inhibitor of P. falciparum Growth |
| Q58699076 | Drug Resistance in |
| Q40041111 | Early treatment failure in concurrent dengue and mixed malaria species infection with suspected resistance to artemisinin combination therapy from a tertiary care center in Delhi: a case report |
| Q30043987 | Esterase mutation is a mechanism of resistance to antimalarial compounds |
| Q92461679 | Evaluation of Antimalarial Activity of Hydromethanolic Crude Extract and Solvent Fractions of the Leaves of Nuxia congesta R. Br. Ex Fresen (Buddlejaceae) in Plasmodium berghei Infected Mice |
| Q91628212 | Evaluation of Antimalarial Activity of the 80% Methanolic Stem Bark Extract of Combretum molle Against Plasmodium berghei in Mice |
| Q92845815 | High-Complexity Plasmodium falciparum Infections, North Central Nigeria, 2015-2018 |
| Q41533469 | Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides |
| Q38795745 | Host-directed therapies for infectious diseases: current status, recent progress, and future prospects |
| Q58695083 | Hydroethanolic Extracts of and Reduced Parasitemia in Balb/c Mice |
| Q64962567 | Impact of training of mothers, drug shop attendants and voluntary health workers on effective diagnosis and treatment of malaria in Lagos, Nigeria. |
| Q38851013 | Improving the Specificity of Plasmodium falciparum Malaria Diagnosis in High-Transmission Settings with a Two-Step Rapid Diagnostic Test and Microscopy Algorithm. |
| Q57471866 | In search of the representative pharmacophore hypotheses of the enzymatic proteome of Plasmodium falciparum: a multicomplex-based approach |
| Q56343057 | In silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1) |
| Q39419051 | In vitro antioxidant and antimalarial activities of leaves, pods and bark extracts of Acacia nilotica (L.) Del |
| Q40129832 | Isolation and Characterization of Vaccine Candidate Genes Including CSP and MSP1 in Plasmodium yoelii |
| Q92170025 | Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro |
| Q64244544 | Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever |
| Q40378874 | Molecular Epidemiology of Plasmodium falciparum kelch13 Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing |
| Q90525463 | Molecular surveillance of anti-malarial drug resistance in Democratic Republic of Congo: high variability of chloroquinoresistance and lack of amodiaquinoresistance |
| Q55429507 | Nanopore sequencing of drug-resistance-associated genes in malaria parasites, Plasmodium falciparum. |
| Q37293213 | Natural Mosquito-Pathogen Hybrid IgG4 Antibodies in Vector-Borne Diseases: A Hypothesis |
| Q91795842 | New Quinolone-Based Thiosemicarbazones Showing Activity Against Plasmodium falciparum and Mycobacterium tuberculosis |
| Q61443798 | Nonconventional opponents: a review of malaria and leishmaniasis among United States Armed Forces |
| Q90971436 | Novel Hydrophilic Riminophenazines as Potent Antiprotozoal Agents |
| Q33560788 | Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening |
| Q56342367 | Opportunities for Host-targeted Therapies for Malaria |
| Q91891454 | Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway |
| Q93011532 | Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation |
| Q47134278 | Potential Sabotage of Host Cell Physiology by Apicomplexan Parasites for Their Survival Benefits |
| Q48018169 | Preliminary Evaluation of Artemisinin-Cholesterol Conjugates as Potential Drugs for the Treatment of Intractable Forms of Malaria and Tuberculosis |
| Q62023931 | Prevalence of chloroquine and antifolate drug resistance alleles in Plasmodium falciparum clinical isolates from three areas in Ghana |
| Q26747055 | Recent advances in understanding apicomplexan parasites |
| Q40047869 | Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. |
| Q99634916 | Role of Melatonin in the Synchronization of Asexual Forms in the Parasite Plasmodium falciparum |
| Q64085889 | Seasonal malaria vector and transmission dynamics in western Burkina Faso |
| Q48022900 | Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules. |
| Q56341482 | The 2015-2016 malaria epidemic in Northern Uganda; what are the implications for malaria control interventions? |
| Q33802977 | The Malaria Parasite Cyclin H Homolog PfCyc1 Is Required for Efficient Cytokinesis in Blood-Stage Plasmodium falciparum |
| Q30042965 | The Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic Screens |
| Q92231044 | The genomic architecture of antimalarial drug resistance |
| Q41149881 | The threat of antimalarial drug resistance |
| Q64245769 | Updating the modified Thompson test by using whole-body bioluminescence imaging to replace traditional efficacy testing in experimental models of murine malaria |
| Q48015411 | Validation of Putative Apicoplast-Targeting Drugs Using a Chemical Supplementation Assay in Cultured Human Malaria Parasites. |
| Q33910481 | Vector control with driving Y chromosomes: modelling the evolution of resistance |
Search more.